Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. Show more
Location: | Website: imaratx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$42.25 - $60.73
Previous Close
$51.35
Open
$51.56
Volume
17,662
Day Range
$50.26 - $53.69
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
16.63%
Institutional Own.
81.32%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|